Literature DB >> 31821122

18F-FDG PET/CT Uptake Classification in Lymphoma and Lung Cancer by Using Deep Convolutional Neural Networks.

Ludovic Sibille1, Robert Seifert1, Nemanja Avramovic1, Thomas Vehren1, Bruce Spottiswoode1, Sven Zuehlsdorff1, Michael Schäfers1.   

Abstract

Background Fluorine 18 (18F)-fluorodeoxyglucose (FDG) PET/CT is a routine tool for staging patients with lymphoma and lung cancer. Purpose To evaluate configurations of deep convolutional neural networks (CNNs) to localize and classify uptake patterns of whole-body 18F-FDG PET/CT images in patients with lung cancer and lymphoma. Materials and Methods This was a retrospective analysis of consecutive patients with lung cancer or lymphoma referred to a single center from August 2011 to August 2013. Two nuclear medicine experts manually delineated foci with increased 18F-FDG uptake, specified the anatomic location, and classified these findings as suspicious for tumor or metastasis or nonsuspicious. By using these expert readings as the reference standard, a CNN was developed to detect foci positive for 18F-FDG uptake, predict the anatomic location, and determine the expert classification. Examinations were divided into independent training (60%), validation (20%), and test (20%) subsets. Results This study included 629 patients (mean age, 52.2 years ± 20.4 [standard deviation]; 394 men). There were 302 patients with lung cancer and 327 patients with lymphoma. For the test set (123 patients; 10 782 foci), the CNN areas under the receiver operating characteristic curve (AUCs) for determining hypermetabolic 18F-FDG PET/CT foci that were suspicious for cancer versus nonsuspicious by using the five input features were as follows: CT alone, 0.78 (95% confidence interval [CI]: 0.72, 0.83); 18F-FDG PET alone, 0.97 (95% CI: 0.97, 0.98); 18F-FDG PET/CT, 0.98 (95% CI: 0.97, 0.99); 18F-FDG PET/CT maximum intensity projection (MIP), 0.98 (95% CI: 0.98, 0.99); and 18F-FDG PET/CT MIP atlas, 0.99 (95% CI: 0.98, 1.00). The combination of 18F-FDG PET and CT information improved overall classification accuracy (AUC, 0.975 vs 0.981, respectively; P < .001). Anatomic localization accuracy of the CNN was 2543 of 2639 (96.4%; 95% CI: 95.5%, 97.1%) for body part, 2292 of 2639 (86.9%; 95% CI: 85.3%, 88.5%) for region (ie, organ), and 2149 of 2639 (81.4%; 95% CI: 79.3%-83.5%) for subregion. Conclusion The fully automated anatomic localization and classification of fluorine 18-fluorodeoxyglucose PET uptake patterns in foci suspicious and nonsuspicious for cancer in patients with lung cancer and lymphoma by using a convolutional neural network is feasible and achieves high diagnostic performance when both CT and PET images are used. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Froelich and Salavati in this issue.

Entities:  

Year:  2019        PMID: 31821122     DOI: 10.1148/radiol.2019191114

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  28 in total

Review 1.  Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions).

Authors:  Navid Hasani; Sriram S Paravastu; Faraz Farhadi; Fereshteh Yousefirizi; Michael A Morris; Arman Rahmim; Mark Roschewski; Ronald M Summers; Babak Saboury
Journal:  PET Clin       Date:  2022-01

2.  A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies.

Authors:  Fanny Orlhac; Jakoba J Eertink; Anne-Ségolène Cottereau; Josée M Zijlstra; Catherine Thieblemont; Michel Meignan; Ronald Boellaard; Irène Buvat
Journal:  J Nucl Med       Date:  2021-09-16       Impact factor: 10.057

3.  Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CT.

Authors:  Maja Guberina; Ken Herrmann; Christoph Pöttgen; Nika Guberina; Hubertus Hautzel; Thomas Gauler; Till Ploenes; Lale Umutlu; Axel Wetter; Dirk Theegarten; Clemens Aigner; Wilfried E E Eberhardt; Martin Metzenmacher; Marcel Wiesweg; Martin Schuler; Rüdiger Karpf-Wissel; Alina Santiago Garcia; Kaid Darwiche; Martin Stuschke
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

4.  Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.

Authors:  Paul Blanc-Durand; Simon Jégou; Salim Kanoun; Alina Berriolo-Riedinger; Caroline Bodet-Milin; Françoise Kraeber-Bodéré; Thomas Carlier; Steven Le Gouill; René-Olivier Casasnovas; Michel Meignan; Emmanuel Itti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10-24       Impact factor: 9.236

5.  Biodistribution of andrographolide to assess the interior-exterior relationship between the lung and intestine using microPET.

Authors:  Qi Zhang; Qingxin Cui
Journal:  Thorac Cancer       Date:  2020-10-05       Impact factor: 3.500

Review 6.  Artificial Intelligence for Response Evaluation With PET/CT.

Authors:  Lise Wei; Issam El Naqa
Journal:  Semin Nucl Med       Date:  2020-11-11       Impact factor: 4.446

Review 7.  Artificial intelligence and hybrid imaging: the best match for personalized medicine in oncology.

Authors:  Martina Sollini; Francesco Bartoli; Andrea Marciano; Roberta Zanca; Riemer H J A Slart; Paola A Erba
Journal:  Eur J Hybrid Imaging       Date:  2020-12-09

8.  Translational Applications of Artificial Intelligence and Machine Learning for Diagnostic Pathology in Lymphoid Neoplasms: A Comprehensive and Evolutive Analysis.

Authors:  Julia Moran-Sanchez; Antonio Santisteban-Espejo; Miguel Angel Martin-Piedra; Jose Perez-Requena; Marcial Garcia-Rojo
Journal:  Biomolecules       Date:  2021-05-25

Review 9.  Applications of artificial intelligence and deep learning in molecular imaging and radiotherapy.

Authors:  Hossein Arabi; Habib Zaidi
Journal:  Eur J Hybrid Imaging       Date:  2020-09-23

10.  New PET technologies - embracing progress and pushing the limits.

Authors:  Nicolas Aide; Charline Lasnon; Adam Kesner; Craig S Levin; Irene Buvat; Andrei Iagaru; Ken Hermann; Ramsey D Badawi; Simon R Cherry; Kevin M Bradley; Daniel R McGowan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-03       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.